GlassScriptPhysician profile
Erol Lale
NPI 1750379202
$4,183.08
in general payments reported to CMS, 2019-2025
21 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $688 · 2021: $884 · 2022: $747 · 2023: $399 · 2024: $195 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $583.39 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $471.96 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $349.94 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $326.69 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.36 | 2019-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.25 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $249.17 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $247.90 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $227.33 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $223.27 | 2019-2022 | |
| Esperion Therapeutics, INC. | $189.45 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $189.04 | 2019-2023 | Xarelto |
| Abbott Laboratories | $178.67 | 2022 | |
| Boston Scientific Corporation | $125.07 | 2019-2023 | Watchman Access System |
| Pfizer INC. | $123.70 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.47 | 2022 | |
| Novo Nordisk INC | $22.00 | 2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $19.77 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Infobionic, INC | $12.10 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erol Lale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.